Trial · NCT06832228
Study of Pomalidomide Combination with Rituximab and Anti-PD-1 Antibody （PPR） in Third or Later Line Therapy of DLBCL
NCT06832228, Not applicable, Unknown, Zhejiang Cancer Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Pomalidomide Combination with Rituximab and Anti-PD-1 Antibody （PPR） in Third or Later Line Therapy of DLBCL. Trials, record NCT06832228. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06832228
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Pomalidomide Combination with Rituximab and Anti-PD-1 Antibody （PPR） in Third or Later Line Therapy of DLBCL
- NCT number
- NCT06832228
- Status
- Unknown
- Phases
- Not applicable
- Enrollment
- 30 participants, estimated
- Lead sponsor
- Zhejiang Cancer Hospital
- Conditions
- Diffuse Large B-cell Lymphoma (DLBCL)
- Interventions
- Pomalidomide Combination With Rituximab and Anti-PD-1 Antibody （PPR）
- First posted
- 2025-02-18
- Last updated
- 2025-02-18
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Response Rate (ORR) | 28days after the end of treatment | The proportion of subjects who achieves a best overall response of CR or PR. |
| Secondary | Complete Remission Rate（CRR） | 28days after the end of treatment | The proportion of subjects who achieves a best overall response of CR. |
| Secondary | Disease-control Rate（DCR） | 28days after the end of treatment | The proportion of subjects response of CR, PR, or SD |
| Secondary | Progression-Free Survival（PFS） | Up to 2 years | From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first |
| Secondary | overall survival（OS） | Up to 2 years | The overall survival time refers to the time from therapy to death due to any cause. |
| Secondary | Adverse event rate | From date of first day of treatment until 30 day after last treatment | The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06832228
GET https://conductscience.org/api/trials/v1/NCT06832228/registered